FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis

Journal of Hepatology

Volumn 59, Issue 6, 2013, Pages 1278-1284

  Wannhoff, Andreas ^a   Hov, Johannes Roksund ^b,c   Folseraas, Trine ^b,c   Rupp, Christian ^a   Friedrich, Kilian ^a   Anmarkrud, Jarl Andreas ^b   Weiss, Karl Heinz ^a   Sauer, Peter ^a   Schirmacher, Peter ^d   Boberg, Kirsten Muri ^b,c   Stremmel, Wolfgang ^a   Karlsen, Tom Hemming ^b   Gotthardt, Daniel Nils ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

CA19 9; Cholangiocarcinoma; Fucosyltransferase 2; Fucosyltransferase 3; Gallbladder carcinoma; Primary sclerosing cholangitis

Indexed keywords

CA 19-9 ANTIGEN; FUCOSYLTRANSFERASE; FUCOSYLTRANSFERASE 2; FUCOSYLTRANSFERASE 3; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BILE DUCT CARCINOMA; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME ACTIVITY; FALSE POSITIVE RESULT; FEMALE; GENE MUTATION; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM;

AASLD; AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES; AREA UNDER THE CURVE; AUC; CA19-9; CARBOHYDRATE ANTIGEN 19-9; CCA; CHOLANGIOCARCINOMA; EASL; EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER; FUCOSYLTRANSFERASE 2; FUCOSYLTRANSFERASE 3; FUT2; FUT3; GALLBLADDER CARCINOMA; GBCA; HD; HEIDELBERG; IBD; INFLAMMATORY BOWEL DISEASE; INTER-QUARTILE RANGE; IQR; LIVER TRANSPLANTATION; LT; MELD; MODEL OF END-STAGE LIVER DISEASE; NEGATIVE PREDICTIVE VALUE; NPV; O; OSLO; POSITIVE PREDICTIVE VALUE; PPV; PRIMARY SCLEROSING CHOLANGITIS; PSC; RECEIVER OPERATING CHARACTERISTIC; ROC; SINGLE-NUCLEOTIDE POLYMORPHISM; SNP; WGA; WHOLE-GENOME AMPLIFIED;

ADULT; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CA-19-9 ANTIGEN; CHOLANGIOCARCINOMA; CHOLANGITIS, SCLEROSING; FEMALE; FUCOSYLTRANSFERASES; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES;

EID: 84888003877     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.08.005     Document Type: Article

References (24)

1. R. Chapman, J. Fevery, A. Kalloo, D.M. Nagorney, K.M. Boberg, and B. Shneider Diagnosis and management of primary sclerosing cholangitis Hepatology 51 2010 660 678
2. A. Bergquist, A. Ekbom, R. Olsson, D. Kornfeldt, L. Loof, and A. Danielsson Hepatic and extrahepatic malignancies in primary sclerosing cholangitis J Hepatol 36 2002 321 327
3. N. Razumilava, G.J. Gores, and K.D. Lindor Cancer surveillance in patients with primary sclerosing cholangitis Hepatology 54 2011 1842 1852
4. H. Narimatsu, H. Iwasaki, F. Nakayama, Y. Ikehara, T. Kudo, and S. Nishihara Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients Cancer Res 58 1998 512 518
5. S. Nishihara, H. Narimatsu, H. Iwasaki, S. Yazawa, S. Akamatsu, and T. Ando Molecular genetic analysis of the human Lewis histo-blood group system J Biol Chem 269 1994 29271 29278
6. J.L. Magnani, Z. Steplewski, H. Koprowski, and V. Ginsburg Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin Cancer Res 43 1983 5489 5492
7. R. Mollicone, I. Reguigne, R.J. Kelly, A. Fletcher, J. Watt, and S. Chatfield Molecular basis for Lewis alpha(1,3/1,4)-fucosyltransferase gene deficiency (FUT3) found in Lewis-negative Indonesian pedigrees J Biol Chem 269 1994 20987 20994
8. N. Storm, B. Darnhofer-Patel, D. van den Boom, and C.P. Rodi MALDI-TOF mass spectrometry-based SNP genotyping Methods Mol Biol 212 2003 241 262
9. B. Cakir, J.S. Pankow, V. Salomaa, D. Couper, T.L. Morris, and K.R. Brantley Distribution of Lewis (FUT3)genotype and allele: frequencies in a biethnic United States population Ann Hematol 81 2002 558 565
10. A. Elmgren, R. Mollicone, M. Costache, C. Borjeson, R. Oriol, and J. Harrington Significance of individual point mutations, T202C and C314T, in the human Lewis (FUT3) gene for expression of Lewis antigens by the human alpha(1,3/1,4)-fucosyltransferase Fuc-TIII. J Biol Chem 272 1997 21994 21998
11. R.J. Kelly, S. Rouquier, D. Giorgi, G.G. Lennon, and J.B. Lowe Sequence and expression of a candidate for the human Secretor blood group alpha(1,2)fucosyltransferase gene (FUT2). Homozygosity for an enzyme-inactivating nonsense mutation commonly correlates with the non-secretor phenotype J Biol Chem 270 1995 4640 4649
12. S. Nishihara, T. Hiraga, Y. Ikehara, H. Iwasaki, T. Kudo, and S. Yazawa Molecular behavior of mutant Lewis enzymes in vivo Glycobiology 9 1999 373 382
13. V. Salomaa, J. Pankow, G. Heiss, B. Cakir, J.H. Eckfeldt, and R.C. Ellison Genetic background of Lewis negative blood group phenotype and its association with atherosclerotic disease in the NHLBI family heart study J Intern Med 247 2000 689 698
14. T.F. Orntoft, E.M. Vestergaard, E. Holmes, J.S. Jakobsen, N. Grunnet, and M. Mortensen Influence of Lewis alpha1-3/4-L-fucosyltransferase (FUT3) gene mutations on enzyme activity, erythrocyte phenotyping, and circulating tumor marker sialyl-Lewis a levels J Biol Chem 271 1996 32260 32268
15. E.M. Vestergaard, H.O. Hein, H. Meyer, N. Grunnet, J. Jorgensen, and H. Wolf Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population Clin Chem 45 1999 54 61
16. U.B. Dogan, Y. Gumurdulu, N. Golge, and B. Kara Relationship of CA 19-9 with choledocholithiasis and cholangitis Turk J Gastroenterol 22 2011 171 177
17. C. Levy, J. Lymp, P. Angulo, G.J. Gores, N. Larusso, and K.D. Lindor The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis Dig Dis Sci 50 2005 1734 1740
18. N. Chalasani, A. Baluyut, A. Ismail, A. Zaman, G. Sood, and R. Ghalib Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study Hepatology 31 2000 7 11
19. D.J. Rea, J.K. Heimbach, C.B. Rosen, M.G. Haddock, S.R. Alberts, and W.K. Kremers Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma Ann Surg 242 2005 451 458 discussion 458-461
20. P. Charatcharoenwitthaya, F.B. Enders, K.C. Halling, and K.D. Lindor Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis Hepatology 48 2008 1106 1117
21. T.R. Church, F. Ederer, and J.S. Mandel Fecal occult blood screening in the Minnesota study: sensitivity of the screening test J Natl Cancer Inst 89 1997 1440 1448
22. E. Sinakos, A.K. Saenger, J. Keach, W.R. Kim, and K.D. Lindor Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma Clin Gastroenterol Hepatol 9 2011 e431
23. T. Folseraas, E. Melum, P. Rausch, B.D. Juran, E. Ellinghaus, and A. Shiryaev Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci J Hepatol 57 2012 366 375
24. European Association for the Study of the Liver EASL clinical practice guidelines: management of cholestatic liver diseases J Hepatol 51 2009 237 267